Back to News
Market Impact: 0.4

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

JNJ
Company FundamentalsCorporate EarningsCorporate Guidance & OutlookAnalyst EstimatesAnalyst InsightsInvestor Sentiment & PositioningHealthcare & BiotechMarket Technicals & Flows
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Johnson & Johnson (JNJ) has recently underperformed the S&P 500, declining 1.1% over the past month, though it remains a highly searched stock. The company is projected to deliver robust year-over-year earnings growth of 24% for the current quarter ($2.53 EPS) and 8.8% for the current fiscal year ($10.86 EPS), with revenue expected to grow 7% to $24.1 billion in the current quarter. JNJ has consistently surpassed consensus EPS and revenue estimates in the last four quarters and currently holds a Zacks Value Style Score of 'B', indicating it trades at a discount to its peers, yet its Zacks Rank #3 (Hold) suggests an expectation of market-perform in the near term.

Analysis

Johnson & Johnson (JNJ) has recently underperformed the broader market and its industry, returning -1.1% over the past month compared to the S&P 500's +1% and the Zacks Large Cap Pharmaceuticals industry's -2.7%. Despite this, JNJ remains a highly searched stock on Zacks.com, indicating significant investor attention. This divergence suggests a potential disconnect between recent price action and underlying fundamental interest. The company is projected to deliver robust growth, with current quarter EPS expected to rise 24% year-over-year to $2.53, and current fiscal year EPS anticipated to increase 8.8% to $10.86. Revenue estimates are also strong, with a 7% year-over-year increase to $24.1 billion projected for the current quarter. JNJ has consistently beaten consensus EPS and revenue estimates in each of the trailing four quarters, demonstrating strong operational execution. While the current quarter's EPS estimate saw a slight -1% revision over the last 30 days, the next fiscal year's EPS estimate improved by +0.8%. Johnson & Johnson holds a Zacks Rank #3 (Hold), suggesting it may perform in line with the broader market in the near term. Furthermore, its Zacks Value Style Score of 'B' indicates the stock is currently trading at a discount relative to its peers.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.